argenx Gelecekteki Büyüme
Future kriter kontrolleri 5/6
argenx kazanç ve gelirin sırasıyla yıllık 21.6% ve 16.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 21.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 20.4% olacağı tahmin edilmektedir.
Anahtar bilgiler
21.6%
Kazanç büyüme oranı
21.11%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 21.1% |
| Gelir büyüme oranı | 16.9% |
| Gelecekteki özkaynak getirisi | 20.44% |
| Analist kapsamı | Good |
| Son güncelleme | 18 May 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Yeni Anlatı • May 20
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.
Anlatı Güncellemesi • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Anlatı Güncellemesi • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Anlatı Güncellemesi • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Anlatı Güncellemesi • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Anlatı Güncellemesi • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Anlatı Güncellemesi • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Anlatı Güncellemesi • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Anlatı Güncellemesi • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Anlatı Güncellemesi • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Anlatı Güncellemesi • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Anlatı Güncellemesi • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Anlatı Güncellemesi • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Anlatı Güncellemesi • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Anlatı Güncellemesi • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Anlatı Güncellemesi • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Anlatı Güncellemesi • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Anlatı Güncellemesi • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Analiz Makalesi • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...Analiz Makalesi • Jun 30
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Yeni Anlatı • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 8,537 | 2,924 | 3,208 | N/A | 22 |
| 12/31/2027 | 7,215 | 2,416 | 3,051 | N/A | 30 |
| 12/31/2026 | 5,930 | 1,757 | 2,552 | N/A | 30 |
| 3/31/2026 | 4,742 | 1,489 | N/A | N/A | N/A |
| 12/31/2025 | 4,236 | 1,292 | 574 | 685 | N/A |
| 9/30/2025 | 3,683 | 1,533 | N/A | N/A | N/A |
| 6/30/2025 | 3,121 | 1,280 | 309 | 404 | N/A |
| 3/31/2025 | 2,643 | 1,064 | N/A | N/A | N/A |
| 12/31/2024 | 2,248 | 833 | -151 | -83 | N/A |
| 9/30/2024 | 1,909 | -40 | N/A | N/A | N/A |
| 6/30/2024 | 1,660 | -204 | -325 | -260 | N/A |
| 3/31/2024 | 1,451 | -328 | N/A | N/A | N/A |
| 12/31/2023 | 1,269 | -295 | -464 | -420 | N/A |
| 9/30/2023 | 1,029 | -234 | N/A | N/A | N/A |
| 6/30/2023 | 835 | -397 | -758 | -654 | N/A |
| 3/31/2023 | 639 | -511 | N/A | N/A | N/A |
| 12/31/2022 | 441 | -710 | -967 | -863 | N/A |
| 9/30/2022 | 286 | -909 | N/A | N/A | N/A |
| 6/30/2022 | 146 | -907 | -874 | -876 | N/A |
| 3/31/2022 | 381 | -595 | N/A | N/A | N/A |
| 12/31/2021 | 528 | -408 | -728 | -607 | N/A |
| 9/30/2021 | 510 | -373 | N/A | N/A | N/A |
| 6/30/2021 | 526 | -319 | -601 | -474 | N/A |
| 3/31/2021 | 206 | -573 | N/A | N/A | N/A |
| 12/31/2020 | 62 | -608 | -404 | -398 | N/A |
| 9/30/2020 | 75 | -535 | N/A | N/A | N/A |
| 6/30/2020 | 70 | -359 | -263 | -255 | N/A |
| 3/31/2020 | 73 | -275 | N/A | N/A | N/A |
| 12/31/2019 | 93 | -181 | N/A | 152 | N/A |
| 9/30/2019 | 72 | -109 | N/A | N/A | N/A |
| 6/30/2019 | 68 | -104 | N/A | 230 | N/A |
| 3/31/2019 | 70 | -47 | N/A | N/A | N/A |
| 12/31/2018 | 33 | -76 | N/A | -62 | N/A |
| 9/30/2018 | 41 | -56 | N/A | N/A | N/A |
| 6/30/2018 | 44 | -47 | N/A | -57 | N/A |
| 3/31/2018 | 50 | -46 | N/A | N/A | N/A |
| 12/31/2017 | 49 | -34 | N/A | -44 | N/A |
| 9/30/2017 | 42 | -30 | N/A | N/A | N/A |
| 6/30/2017 | 39 | -25 | N/A | -31 | N/A |
| 3/31/2017 | 23 | -29 | N/A | N/A | N/A |
| 12/31/2016 | 18 | -22 | N/A | 11 | N/A |
| 9/30/2016 | 17 | -20 | N/A | N/A | N/A |
| 6/30/2016 | 14 | -17 | N/A | 16 | N/A |
| 3/31/2016 | 12 | -17 | N/A | N/A | N/A |
| 12/31/2015 | 11 | -17 | N/A | -15 | N/A |
| 9/30/2015 | 10 | -16 | N/A | N/A | N/A |
| 6/30/2015 | 9 | -14 | N/A | -10 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARGX 'nin tahmini kazanç büyümesi (yıllık 21.6% ) tasarruf oranının ( 2.4% ) üzerindedir.
Kazançlar ve Piyasa: ARGX şirketinin kazançlarının (yıllık 21.6% ) Belgian pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: ARGX şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: ARGX şirketinin gelirinin (yıllık 16.9% ) Belgian pazarından (yıllık 6.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ARGX şirketinin gelirinin (yıllık 16.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARGX 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 20.4 %)
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 18:46 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
argenx SE 55 Bu analistlerden 30, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |